Inhibikase Therapeutics (IKT) Debt to Equity (2019 - 2026)
Inhibikase Therapeutics (IKT) debt to equity from Dec 31, 2019 to Mar 31, 2026. The current Inhibikase Therapeutics (IKT) debt to equity is 0.00%. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Debt to Equity
Debt to Equity
Annual Debt to Equity change of Inhibikase Therapeutics (IKT)
| Year | Debt to Equity | Change |
|---|---|---|
| 2025 | 0.00% | N/A |
| 2024 | 0.00% | -100.00% |
| 2023 | 3.46% | N/A |
| 2022 | 0.00% | -100.00% |
| 2021 | 0.65% | N/A |
| 2020 | 0.00% | N/A |
| 2019 | 0.00% | N/A |